Affymax Overview

The new Affymax (NASDAQ: AFFY) is building upon its proven discovery platform and extensive pharmaceutical experience to build a pipeline of peptide drugs to treat cancer and immune-mediated diseases. The powerful combination of broad management experience, clinical development know-how, a proven drug discovery engine and strong intellectual property, positions Affymax as a preeminent drug...More»

The new Affymax (NASDAQ: AFFY) is building upon its proven discovery platform and extensive pharmaceutical experience to build a pipeline of peptide drugs to treat cancer and immune-mediated diseases. The powerful combination of broad management experience, clinical development know-how, a proven drug discovery engine and strong intellectual property, positions Affymax as a preeminent drug discovery and development company. The Company has been a pioneer in chemistry and high throughput screening technologies that enable faster and more efficient processes for drug discovery by integrating proprietary chemistries, innovative molecular biology techniques, sophisticated software and instrumentation technology.«Less